C2N Diagnostics
BiotechnologyView the employees at
C2N Diagnostics-
Kris Kirmess Director of Clinical Chemistry & Commercial Assays at C2N Diagnostics
-
Greater St. Louis
-
Top 5%
Dewayne Jennings Systems and Technology Manager at C2N Diagnostics-
Rising Star
Konstantin Makarov R&D Laboratory Manager at C2N Diagnostics-
St Louis, Missouri, United States
-
Rising Star
Chad Thieman BioPharma Business Leader | Senior Account Management & Sales Leader | Revenue Growth | Operations Management | Product Launch-
Rising Star
Todd Koeppel IT Quality Assurance Manager at C2N Diagnostics-
Sandpoint, Idaho, United States
-
Top 10%
Overview
C₂N Diagnostics’ vision is to bring Clarity Through Innovation™. It focuses its therapeutic discovery efforts around mechanism-based approaches to prevent or stop the progression of human neurological disorders. Diagnostic efforts revolve around bringing accurate, widely accessible, and cost-effective blood tests to the clinic for the betterment of patient care and brain health monitoring. Its lead commercial product, the PrecivityAD™ blood test, is a mass spectrometry-based test performed in C₂N’s CLIA-certified lab that measures in blood multiple analytes including Aβ42, Aβ40, and apolipoprotein E isoforms. While the test by itself cannot diagnose Alzheimer’s disease — which is a clinical diagnosis made by a health care provider — the test is an important new tool for physicians to aid in the evaluation process. PrecivityAD™, which can only be ordered through a health care provider, predicts brain amyloid plaques as determined by PET scan results and in 2019 it received a Breakthrough Device Designation from the U.S. Food and Drug Administration. The PrecivityAD™ blood test also has achieved the CE Mark from the European Union. For more information visit www.C2N.com.
-